Global Influenza Vaccine Market - Industry Trends, Opportunities and Forecasts to 2023

November 2017 | 120 pages | ID: GC5CC7AFD5BEN
Knowledge Sourcing Intelligence LLP

Abstracts

The global influenza vaccine market is projected to witness a CAGR of 6.93% during the forecast period to reach a total market size of US$4.613 billion by 2023, increasing from US$3.300 billion in 2018. The influenza, also called flu, is a contagious respiratory illness caused by influenza viruses that infect the nose, throat, and sometimes the lungs. It can cause mild to severe illness, and at times can lead to death. The major factors driving the demand for the market are basically the increasing awareness about the pandemic influenza viruses and the increasing government initiatives for vaccination against influenza. The major restrains of this market are variable demand, limited production capacity, a high level of required investment, and strict regulations present barriers to new entrants.

The development of quadrivalent vaccines has gained increased popularity lately. Influenza vaccines were designed to protect against three different flu viruses (trivalent). This included an influenza A H1N1 virus, an influenza A H3N2 virus and one B virus. But the trivalent vaccines did not cover the entire type B virus and as such, quadrivalent vaccines were developed. The addition of another B virus to the vaccine aims to give broader protection against circulating flu viruses.

The proliferation of influenza vaccine market grew rapidly in the USA on account of factors such as increased disease awareness, government regulations and policies favouring the vaccine consumption. Moreover, Asia Pacific market for influenza vaccine is projected to grow rapidly on account of increasing the coverage area, unlocking the untapped potential, and the rising government awareness programme.

The global influenza vaccine market is highly consolidated with major players dominating the market share. The entry is fairly restricted in the market due to strict regulatory compliance requirement. The competitive landscape details strategies, products, and investments being done by key players in different technologies and companies to boost their market presence.

Some of the major players discussed in the report are Seqirus, GlaxoSmithKilne plc, Sanofi Pasteur SA, and Merck Sharp & Dohme Corp among others.

Segmentation

The global influenza vaccine market has been segmented by vaccine, end-user, and geography.

By Vaccine
Trivalent
Quadrivalent
By End-User
Children and Adolescent
Adult
Elderly
By Geography
North America
USA
Canada
Mexico
Europe
Germany
France
Italy
Spain
UK
Middle East and Africa
Asia Pacific
China
Japan
India
South Korea
South America
Argentina
Brazil
Chile

Contents

1. INTRODUCTION

1.1. Market Definition
1.2. Scope of the Study
1.3. Currency
1.4. Assumptions
1.5. Base, and Forecast Years Timeline

2. RESEARCH METHODOLOGY

2.1. Research Design
2.2. Secondary Sources
2.3. Validation

3. KEY FINDINGS OF THE STUDY

4. MARKET DYNAMICS

4.1. Drivers
4.2. Restraints
4.3. Opportunities and Market Trends
4.4. Market Segmentation
4.5. Prevalence
4.6. Product Pipeline
4.7. Innovations
4.8. Industry Regulations
4.9. Scenario Analysis

5. GLOBAL INFLUENZA VACCINE MARKET FORECAST BY VACCINE (US$ BILLION)

5.1. Introduction
5.2. Trivalent
5.3. Quadrivalent

6. GLOBAL INFLUENZA VACCINE MARKET FORECAST BY END-USER (US$ BILLION)

6.1. Introduction
6.2. Children and Adolescent
6.3. Adults
6.4. Elderly

7. GLOBAL INFLUENZA VACCINE MARKET FORECAST BY GEOGRAPHY (US$ BILLION)

7.1. Introduction
7.2. North America
  7.2.1. USA
  7.2.2. Canada
  7.2.3. Mexico
7.3. Europe
  7.3.1. Germany
  7.3.2. France
  7.3.3. Italy
  7.3.4. Spain
  7.3.5. UK
7.4. Middle east and Africa
7.5. Asia Pacific
  7.5.1. China
  7.5.2. Japan
  7.5.3. India
  7.5.4. South Korea
7.6. South America
  7.6.1. Argentina
  7.6.2. Brazil
  7.6.3. Chile

8. COMPETITIVE INTELLIGENCE

8.1. Market Share Analysis
8.2. Strategies of Key Players
8.3. Recent Investments And Deals

9. COMPANY PROFILES

9.1. Seqirus
  9.1.1. Overview
  9.1.2. Financials
  9.1.3. Product and Services
  9.1.4. Key Developments
9.2. GlaxoSmithKline plc
  9.2.1. Overview
  9.2.2. Financials
  9.2.3. Products and Services
  9.2.4. Key Developments
9.3. Sanofi Pasteur SA
  9.3.1. Overview
  9.3.2. Financials
  9.3.3. Products and Services
  9.3.4. Key Developments
9.4. MedImmune
  9.4.1. Overview
  9.4.2. Financials
  9.4.3. Products and Services
  9.4.4. Key Developments
9.5. CSL Limited
  9.5.1. Overview
  9.5.2. Financials
  9.5.3. Products and Services
  9.5.4. Key Developments
9.6. Merck Sharp & Dohme Corp.
  9.6.1. Overview
  9.6.2. Financials
  9.6.3. Products and Services
  9.6.4. Key Developments
9.7. Pfizer, Inc.
  9.7.1. Overview
  9.7.2. Financials
  9.7.3. Products and Services
  9.7.4. Key Developments
9.8. Gamma Vaccines Pty Ltd
  9.8.1. Overview
  9.8.2. Financials
  9.8.3. Product and Services
  9.8.4. Key Developments
9.9. Sinovac Biotech Ltd
  9.9.1. Overview
  9.9.2. Financials
  9.9.3. Product and Services
  9.9.4. Key Developments
9.10. OPKO Health, Inc.
  9.10.1. Overview
  9.10.2. Financials
  9.10.3. Product and Services
  9.10.4. Key Developments